Cantor Fitzgerald Forecasts SI-BONE FY2026 Earnings

SI-BONE, Inc. (NASDAQ:SIBN) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for SI-BONE in a report released on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will earn ($0.10) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million.

Other analysts have also issued research reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $24.00 price target on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial boosted their target price on shares of SI-BONE from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th.

SI-BONE Trading Up 1.3%

Shares of SI-BONE stock opened at $19.10 on Wednesday. SI-BONE has a 52-week low of $11.70 and a 52-week high of $20.05. The firm has a market capitalization of $813.95 million, a PE ratio of -20.76 and a beta of 0.94. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The company’s fifty day moving average price is $16.30 and its two-hundred day moving average price is $15.63.

Insider Activity at SI-BONE

In related news, CEO Laura Francis sold 38,504 shares of the company’s stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $17.18, for a total value of $661,498.72. Following the completion of the transaction, the chief executive officer now directly owns 302,958 shares of the company’s stock, valued at approximately $5,204,818.44. This represents a 11.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey W. Dunn sold 3,377 shares of the company’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $19.05, for a total value of $64,331.85. Following the transaction, the director now directly owns 17,354 shares of the company’s stock, valued at $330,593.70. This represents a 16.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 95,942 shares of company stock worth $1,734,203. 4.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On SI-BONE

A number of institutional investors and hedge funds have recently modified their holdings of the company. Legato Capital Management LLC raised its holdings in SI-BONE by 9.1% in the 4th quarter. Legato Capital Management LLC now owns 62,707 shares of the company’s stock valued at $879,000 after acquiring an additional 5,209 shares during the period. Rhumbline Advisers grew its position in shares of SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock valued at $808,000 after purchasing an additional 1,683 shares during the last quarter. Impax Asset Management Group plc grew its position in shares of SI-BONE by 1.1% in the fourth quarter. Impax Asset Management Group plc now owns 766,761 shares of the company’s stock valued at $10,750,000 after purchasing an additional 8,240 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of SI-BONE during the fourth quarter worth approximately $155,000. Finally, Versor Investments LP acquired a new stake in SI-BONE during the 4th quarter worth approximately $185,000. 98.11% of the stock is owned by institutional investors.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.